MPO and E-selectin Inhibitors for G-CSF Vascular Safety

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Granulocyte colony-stimulating factor (G-CSF) administration is associated with significant vascular complications, including angina pectoris, myocardial infarct, and leukocytoclastic vasculitis, due to increased adhesive interactions of G-CSF-mobilized leukocytes with cytokine-stimulated vascular endothelium, and there is a need to prevent these adverse effects while retaining the therapeutic benefits of G-CSF.

Innovation Solution

The use of inhibitors, such as anti-MPO-EL antibodies, MPO inhibitors, and small molecules like peptides and oligonucleotides, to block the interaction between E-selectin receptors and MPO-EL, a potent E-selectin ligand expressed on myeloid cells, which are induced by G-CSF, to prevent vascular complications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If G-CSF administration is used to stimulate myelopoiesis and mobilize progenitor cells, then therapeutic benefits are achieved, but vascular complications and tissue injury occur due to increased adhesive interactions of leukocytes with endothelium

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidvascular complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses E-selectin inhibitors as intermediary substances that block the harmful interaction between G-CSF-mobilized leukocytes and vascular endothelium. The inhibitor acts as a mediator that prevents the adhesive interaction without interfering with the therapeutic action of G-CSF on hematopoietic stem cells, thereby resolving the contradiction between therapeutic efficacy and vascular safety

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent extracts and targets the specific harmful component (E-selectin-mediated adhesion) from the overall G-CSF biological effect. By selectively inhibiting only the E-selectin pathway responsible for vascular complications while leaving other G-CSF functions intact, the treatment achieves therapeutic benefits without the harmful vascular side effects

Inventive Principle:

Principle #2Taking out (Extraction)

2Productivity

If G-CSF induces expression of E-selectin ligands on myeloid cells to enhance leukocyte production, then myelopoiesis is stimulated, but adhesive interactions with vascular endothelium increase causing vasculitis and myocardial infarction

Engineering Contradiction:

Improveleukocyte productionVSAvoidadhesive interactions

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful adhesive property of E-selectin ligands into a beneficial target for selective inhibition. By developing inhibitors that specifically block E-selectin-ligand interactions, the harmful adhesive effect is neutralized while the productive leukocyte production function is preserved, effectively converting a harmful byproduct into a controlled therapeutic parameter

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These inhibitors effectively reduce the severity of G-CSF-induced vascular complications by interrupting E-selectin receptor/ligand interactions and MPO activity, thereby minimizing tissue injury and inflammation, including conditions like myocardial infarction and atherosclerosis.

Implementation Method 1

administering to a subject in need thereof an agent which inhibits E-selectin-mediated interaction with a selectin ligand

Methodology Applied

Scientific EffectAntibody-antigen interaction:

Implementation Method 2

administering to a subject in need thereof an inhibitor of myeloperoxidase enzymatic activity

Methodology Applied

Scientific EffectEnzyme inhibition:

Implementation Method 3

Granulocyte colony-stimulating factor (G-CSF or GCSF) is a hematopoietic cytokine that stimulates leukocyte production and activation

Methodology Applied

Scientific EffectCytokine-receptor interaction:

Implementation Method 4

Phagocytosis induces a respiratory burst accompanied by creation of superoxide anion (O2−) and hydrogen peroxide (H2O2)

Methodology Applied

Scientific EffectRespiratory burst:

Implementation Method 5

The lysosomal enzyme myeloperoxidase (MPO) then uses hydrogen peroxide together with halide electron donors (Cl−, I−) to synthesize toxic and more efficient ROS like hypohalous acids (HClO, HIO)

Methodology Applied

Scientific EffectEnzymatic oxidation:

Implementation Method 6

These inhibitors effectively reduce the severity of G-CSF-induced vascular complications by interrupting E-selectin receptor/ligand interactions and MPO activity

Methodology Applied

Scientific EffectReceptor-ligand interaction blocking:

Data Source

PatentUS8765126B2Methods of treating complications and disorders associated with G-CSF administration

Publication Date: 2014.07.01 SACKSTEIN ROBERT

AI summary

The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).